Literature DB >> 10871291

Endocannabinoids and vascular function.

C J Hillard1.   

Abstract

Marijuana is used by humans for its psychoactive and medicinal effects. The active constituents of marijuana, the cannabinoids, exert effects via a G protein-coupled receptor, CB(1). Two arachidonic acid analogs, N-arachidonylethanolamine and 2-arachidonylglycerol are hypothesized to function as endogenous ligands of the CB(1) receptor. The cannabinoids exert significant vascular effects in humans and laboratory animals. In particular, the cannabinoids produce vasodilation and hypotension. The possible mechanisms for these effects are inhibition of transmitter release from sympathetic nerve terminals, direct effects on vascular smooth muscle cells, and effects on endothelial cell function. The data regarding these effects of the cannabinoids and possible sources of endocannabinoid ligands in the vasculature are the subjects of this review.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10871291

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  51 in total

1.  Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus.

Authors:  J J Rodriguez; K Mackie; V M Pickel
Journal:  J Neurosci       Date:  2001-02-01       Impact factor: 6.167

Review 2.  The complexities of the cardiovascular actions of cannabinoids.

Authors:  Michael D Randall; David A Kendall; Saoirse O'Sullivan
Journal:  Br J Pharmacol       Date:  2004-05       Impact factor: 8.739

Review 3.  Endocannabinoids and exercise.

Authors:  A Dietrich; W F McDaniel
Journal:  Br J Sports Med       Date:  2004-10       Impact factor: 13.800

4.  Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors.

Authors:  Sándor Bátkai; Pál Pacher; Zoltán Járai; Jens A Wagner; George Kunos
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-04-01       Impact factor: 4.733

5.  Hemorrhagic stroke following use of the synthetic marijuana "spice".

Authors:  David Z Rose; Waldo R Guerrero; Maxim V Mokin; Clifton L Gooch; Andrea C Bozeman; Julia M Pearson; W Scott Burgin
Journal:  Neurology       Date:  2015-08-28       Impact factor: 9.910

6.  WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Authors:  David A Price; Alex A Martinez; Alexandre Seillier; Wouter Koek; Yolanda Acosta; Elizabeth Fernandez; Randy Strong; Beat Lutz; Giovanni Marsicano; James L Roberts; Andrea Giuffrida
Journal:  Eur J Neurosci       Date:  2009-05-21       Impact factor: 3.386

7.  Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment.

Authors:  Matthew N Hill; Erica J Carrier; Ryan J McLaughlin; Anna C Morrish; Sarah E Meier; Cecilia J Hillard; Boris B Gorzalka
Journal:  J Neurochem       Date:  2008-07-15       Impact factor: 5.372

Review 8.  Adaptations of striatal endocannabinoid system during stress.

Authors:  Silvia Rossi; Valentina De Chiara; Alessandra Musella; Giorgia Mataluni; Lucia Sacchetti; Giorgio Bernardi; Alessandro Usiello; Diego Centonze
Journal:  Mol Neurobiol       Date:  2009-03-07       Impact factor: 5.590

9.  Cannabinoid receptor activation in the rostral ventrolateral medulla oblongata evokes cardiorespiratory effects in anaesthetised rats.

Authors:  James R Padley; Qun Li; Paul M Pilowsky; Ann K Goodchild
Journal:  Br J Pharmacol       Date:  2003-08-04       Impact factor: 8.739

10.  Increased angiotensin II contraction of the uterine artery at early gestation in a transgenic model of hypertensive pregnancy is reduced by inhibition of endocannabinoid hydrolysis.

Authors:  Victor M Pulgar; Liliya M Yamaleyeva; Jasmina Varagic; Carolynne M McGee; Michael Bader; Ralf Dechend; Allyn C Howlett; K Bridget Brosnihan
Journal:  Hypertension       Date:  2014-06-16       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.